Rhythm Pharmaceuticals (RYTM) Short-term Investments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Short-term Investments for 11 consecutive years, with $278.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 33.64% year-over-year to $278.5 million; the TTM figure through Mar 2026 stood at $278.5 million (up 33.64% YoY), while the FY2025 annual figure was $334.6 million, up 44.6% from the prior year.
• Short-term Investments eased to $278.5 million in Q1 2026 per RYTM's latest filing, from $334.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $364.0 million in Q3 2025 and bottomed at $122.4 million in Q2 2022.
• Historically, Short-term Investments has averaged $209.1 million across 5 years, with a median of $205.6 million in 2022.
• Annual changes were most pronounced in 2022 — Short-term Investments tumbled 59.04% — and 2025, when it jumped 45.09%.
• Rhythm Pharmaceuticals' Short-term Investments stood at $205.6 million in 2022, then rose by 4.94% to $215.8 million in 2023, then grew by 7.26% to $231.4 million in 2024, then soared by 44.6% to $334.6 million in 2025, then slipped by 16.78% to $278.5 million in 2026.
• Business Quant data shows RYTM's Short-term Investments at $278.5 million in Q1 2026, $334.6 million in Q4 2025, and $364.0 million in Q3 2025.